CA2717692C - N-substituted benzenepropanamide or benzenepropenamide derivatives for use in the treatment of pain and inflammation - Google Patents

N-substituted benzenepropanamide or benzenepropenamide derivatives for use in the treatment of pain and inflammation Download PDF

Info

Publication number
CA2717692C
CA2717692C CA2717692A CA2717692A CA2717692C CA 2717692 C CA2717692 C CA 2717692C CA 2717692 A CA2717692 A CA 2717692A CA 2717692 A CA2717692 A CA 2717692A CA 2717692 C CA2717692 C CA 2717692C
Authority
CA
Canada
Prior art keywords
compound
compounds
pain
treatment
ch2o
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2717692A
Other languages
English (en)
French (fr)
Other versions
CA2717692A1 (en
Inventor
Eliahu Kaplan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novaremed Ltd
Original Assignee
Novaremed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaremed Ltd filed Critical Novaremed Ltd
Publication of CA2717692A1 publication Critical patent/CA2717692A1/en
Application granted granted Critical
Publication of CA2717692C publication Critical patent/CA2717692C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/90—Carboxylic acid amides having nitrogen atoms of carboxamide groups further acylated
    • C07C233/91—Carboxylic acid amides having nitrogen atoms of carboxamide groups further acylated with carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/003—Compounds containing elements of Groups 2 or 12 of the Periodic Table without C-Metal linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polyethers (AREA)
CA2717692A 2008-03-06 2009-03-06 N-substituted benzenepropanamide or benzenepropenamide derivatives for use in the treatment of pain and inflammation Expired - Fee Related CA2717692C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0804213.7 2008-03-06
GBGB0804213.7A GB0804213D0 (en) 2008-03-06 2008-03-06 A method of printing or preventing pain
PCT/IB2009/000448 WO2009109850A2 (en) 2008-03-06 2009-03-06 A method of treating or preventing pain

Publications (2)

Publication Number Publication Date
CA2717692A1 CA2717692A1 (en) 2009-09-11
CA2717692C true CA2717692C (en) 2016-06-07

Family

ID=39327664

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2717692A Expired - Fee Related CA2717692C (en) 2008-03-06 2009-03-06 N-substituted benzenepropanamide or benzenepropenamide derivatives for use in the treatment of pain and inflammation

Country Status (12)

Country Link
US (2) US8883853B2 (enExample)
EP (1) EP2323644B1 (enExample)
JP (1) JP5657394B2 (enExample)
AU (1) AU2009220931B2 (enExample)
CA (1) CA2717692C (enExample)
DK (1) DK2323644T3 (enExample)
ES (1) ES2505325T3 (enExample)
GB (1) GB0804213D0 (enExample)
IL (1) IL207965A (enExample)
PL (1) PL2323644T3 (enExample)
PT (1) PT2323644E (enExample)
WO (1) WO2009109850A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4939396B2 (ja) 2004-03-26 2012-05-23 ノヴァレメッド リミテッド Ａｉｄｓ及び他のウイルス性疾患及びｈｉｖ関連感染症の改善又はその治療用化合物及びそのような化合物を含む組成物、そのような疾患及び感染症の治療方法及びそのような化合物及び組成物の製造方法
GB0804213D0 (en) 2008-03-06 2008-04-16 New Era Biotech Ltd A method of printing or preventing pain
US8802734B2 (en) 2009-09-09 2014-08-12 Novaremed Limited Method of treating or preventing pain
CN102821761B (zh) * 2009-09-09 2015-06-10 诺瓦麦有限公司 用于治疗疼痛和炎症的n-取代的苯丙酰胺或苯丙烯酰胺
GB201116335D0 (en) * 2011-09-21 2011-11-02 Novaremed Ltd A method of treating or preventing affective disorders
AU2012348529B2 (en) * 2011-12-08 2017-03-30 Novaremed Ltd. Isolated stereoisomeric forms of (S) 2-N (3-O-(propan 2-ol) -1-propyl-4-hydroxybenzene) -3-phenylpropylamide
SG11202111773QA (en) 2019-01-23 2021-11-29 Novaremed Ltd Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity
EP3939578A1 (en) 2020-07-13 2022-01-19 Novaremed Ltd. Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2908691A (en) * 1958-07-14 1959-10-13 Searle & Co Hydroxyphenalkylaminoalkylindoles and ethers corresponding thereto
GB1037655A (en) * 1964-05-20 1966-08-03 Koninklijke Pharma Fab Nv Di(aralkyl)amines
ZA732136B (en) 1972-04-12 1974-03-27 Lilly Co Eli Dopamine derivatives
JPS5236606A (en) 1975-09-12 1977-03-22 Tanabe Seiyaku Co Ltd Process for preparation of amino compounds
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4908322A (en) * 1985-09-06 1990-03-13 The United States Of America As Represented By The Department Of Health And Human Services Derivatization of amines for electrochemical detection
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
JP2848232B2 (ja) 1993-02-19 1999-01-20 武田薬品工業株式会社 アルデヒド誘導体
AU1463997A (en) * 1995-12-22 1997-07-17 Acea Pharmaceuticals, Inc. Subtype-selective nmda receptor ligands and the use thereof
WO1997029079A1 (en) 1996-02-06 1997-08-14 Japan Tobacco Inc. Novel compounds and pharmaceutical use thereof
JP2941230B2 (ja) * 1997-05-06 1999-08-25 コナミ株式会社 画像表示処理装置，画像表示処理方法，及びコンピュータプログラムを記録した機械読取り可能な記録媒体
AU2002224139A1 (en) 2000-12-05 2002-06-18 Nippon Chemiphar Co. Ltd. Ppar (peroxisome proliferator activated receptor) activators
JP4667870B2 (ja) * 2002-10-03 2011-04-13 ノヴァレメッド リミテッド 自己免疫疾患、免疫−アレルギー疾患及び臓器又は組織移植拒絶反応の治療において使用する新規な化合物
WO2004047743A2 (en) * 2002-11-22 2004-06-10 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
JP4939396B2 (ja) * 2004-03-26 2012-05-23 ノヴァレメッド リミテッド Ａｉｄｓ及び他のウイルス性疾患及びｈｉｖ関連感染症の改善又はその治療用化合物及びそのような化合物を含む組成物、そのような疾患及び感染症の治療方法及びそのような化合物及び組成物の製造方法
DE102004039373A1 (de) * 2004-08-12 2006-02-23 Grünenthal GmbH Para-Alkyl-substituierte N-(4-Hydroxy-3-methoxy-benzyl)-zimtsäureamide und deren Verwendung zur Herstellung von Arzneimitteln
RU2309144C2 (ru) * 2005-03-25 2007-10-27 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фенилсодержащие n-ацильные производные аминов, способ их получения, фармацевтическая композиция и их применение в качестве противовоспалительных и анальгетических средств
PL2026775T3 (pl) 2006-05-09 2015-12-31 Novaremed Ltd Zastosowanie inhibitorów kinazy tyrozynowej Syk w leczeniu komórkowych zaburzeń proliferacyjnych
WO2009039218A2 (en) 2007-09-17 2009-03-26 Chi-Huey Wong Compositions and methods for treating inflammation and inflammation-related disorders by plectranthus amboinicus extracts
GB0804213D0 (en) 2008-03-06 2008-04-16 New Era Biotech Ltd A method of printing or preventing pain
CN101503370B (zh) 2009-03-02 2012-08-22 上海应用技术学院 一种n-环丙基-反-2-顺-6-壬二烯酸酰胺的合成方法
CN101503373B (zh) 2009-03-13 2013-07-24 山东大学 2-氨基-1-(4-硝基苯基)-1-乙醇类金属蛋白酶抑制剂及其制备方法和用途
US8802734B2 (en) * 2009-09-09 2014-08-12 Novaremed Limited Method of treating or preventing pain

Also Published As

Publication number Publication date
US8883853B2 (en) 2014-11-11
AU2009220931A1 (en) 2009-09-11
EP2323644A2 (en) 2011-05-25
PL2323644T3 (pl) 2014-10-31
IL207965A0 (en) 2010-12-30
AU2009220931B2 (en) 2014-11-13
WO2009109850A2 (en) 2009-09-11
GB0804213D0 (en) 2008-04-16
CA2717692A1 (en) 2009-09-11
PT2323644E (pt) 2014-07-25
DK2323644T3 (da) 2014-07-21
US20110039936A1 (en) 2011-02-17
WO2009109850A3 (en) 2009-12-10
US9199917B2 (en) 2015-12-01
JP2011513377A (ja) 2011-04-28
IL207965A (en) 2015-10-29
JP5657394B2 (ja) 2015-01-21
EP2323644B1 (en) 2014-04-23
ES2505325T3 (es) 2014-10-09
US20150080473A1 (en) 2015-03-19

Similar Documents

Publication Publication Date Title
US9199917B2 (en) N-substituted benzenepropanamide or benzenepropenamide derivatives for use in the treatment of pain and inflammation
EP1399161B1 (en) Sustained-release analgesic compounds
JP5371790B2 (ja) 睡眠および認知に関するうつ病における残存症状の治療のための組み合わされたセロトニン再取り込み、５−ｈｔ３および５−ｈｔ１ａ活性を有する化合物としての１−［２−（２，４−ジメチルフェニルスルファニル）フェニル］ピペラジン
KR101698028B1 (ko) 수용성 아세트아미노펜 유사체
US20160317479A1 (en) Method of treating or preventing pain
JP6016179B2 (ja) 疼痛の治療又は予防用医薬組成物
CN109758452A (zh) 胺类化合物治疗疼痛的医药用途
CN1107333A (zh) 那布扶林镇痛剂的长效前体药物及其制备方法
CN111094259B (zh) 止痛化合物
EP2322164A2 (en) Carbonylamino derivatives useful for the treatment of inflammatory bowel disease
CA3118996A1 (en) Polymorphic form of (s,s)-2-n(3-0-(propan-2- ol)-1-propyl- 4-hydroxybenzene)-3- phenylpropylamide and use thereof in the treatment of pain, inflammation and autoimmunity
HK1179523B (en) N-substituted benzenepropanamide or benzenepropenamide for use in the treatment of pain and inflammation
US9937262B2 (en) Prodrugs of naproxen and diclofenac
CN115697316B (zh) 加巴喷丁和酮洛芬的协同掺加物、药物组合物及其医疗用途
CZ2006623A3 (cs) Kombinace deramciklanu a opioidů jako analgetik
HK40061961B (en) Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity
HK40061961A (en) Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity
UA119070C2 (uk) ЗАСТОСУВАННЯ 5-МЕТИЛ-3-АРИЛ[1,2,4]ТРИАЗОЛО[4,3-a]ПІРИМІДИН-7-ОЛІВ ЯК СПОЛУК, ЩО МАЮТЬ АНАЛГЕТИЧНУ АКТИВНІСТЬ
HK1140683A (en) 1-[2-(2-4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of pain or residual symptoms in depression relating to sleep and cognition
WO2015128697A1 (en) Novel compounds having anti-allodynic and antihyperalgesic activity

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140305

MKLA Lapsed

Effective date: 20220307